Contrarius Group Holdings LTD Intellia Therapeutics, Inc. Transaction History
Contrarius Group Holdings LTD
- $1.46 Trillion
- Q1 2025
A detailed history of Contrarius Group Holdings LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Contrarius Group Holdings LTD holds 2,021,040 shares of NTLA stock, worth $27.3 Million. This represents 0.98% of its overall portfolio holdings.
Number of Shares
2,021,040
Previous 1,011,863
99.73%
Holding current value
$27.3 Million
Previous $11.8 Billion
21.79%
% of portfolio
0.98%
Previous 0.72%
Shares
2 transactions
Others Institutions Holding NTLA
# of Institutions
339Shares Held
98.3MCall Options Held
784KPut Options Held
713K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$176 Million1.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.8MShares$145 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$129 Million0.0% of portfolio
-
State Street Corp Boston, MA4.51MShares$60.8 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.8MShares$51.3 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.03B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...